Drug Utilization Review (DUR) Meeting Minutes
September 2, 2015

Members Present: Tanya Schmidt, Laura Schield, Katie Kram, Wendy Brown, Michael Quast, Russ Sobotta, Peter Woodrow, Andrea Honeyman, Jeffrey Hostetter, Carlotta McCleary

Members Absent: James Carlson, Steve Irsfeld, Michael Booth, Gary Betting

Medicaid Pharmacy Department: Brendan Joyce, Alexi Murphy

W. Brown called the meeting to order at 1:00 p.m. Chair W. Brown asked for a motion to approve the minutes of the June meeting. T. Schmidt moved that the minutes be approved, and L. Schield seconded the motion. Chair W. Brown called for a voice vote to approve the minutes. The motion passed with no audible dissent.

DUR Board new member:
B. Joyce introduced Andrea Honeyman as the most recent pharmacist appointed to the DUR Board.

Second reviews
A motion and second were made at the June meeting to place PCSK9 inhibitors, injectable anticoagulants, Akynzeo, Nuvessa, and Cholbam on prior authorization. The topics were brought up for a second review. Corinne Copeland and Ronda Copher, representing Eisai spoke regarding Akynzeo. The motion to place these medications on prior authorization passed with no audible dissent.

Update on medications > $3,000
A. Murphy gave an update on medications that have been added to the > $3,000 prior authorization list. Cholbam, Natpara, and Orkambi are the most recent additions.

Sanford Health Plan update
Michael Crandell, Else Umbreti and Bill Ladwig gave an update on Medicaid expansion in North Dakota. Michael Crandell is the Chief Medical Officer of Sanford Health Plan.

Prior authorization update on current drugs/classes
A. Murphy gave an update on drugs that have been added to prior authorization. Technivie, Tudorza, Arcapta, Daklinza, Brovana, Vimizim, and Promacta have all been added to prior authorization. Also, hepatitis C medications will soon be considered under the supplemental rebate program. A review of the forms and criteria for these agents will be on the agenda for December.

Movantik review
B. Joyce reviewed Movantik with the Board. B. Haas, representing AstraZeneca, spoke. A motion was made by M. Quast to place Movantik on prior authorization. J. Hostetter seconded the motion. This topic will be reviewed at the next meeting.

Marinol review
B. Joyce reviewed Marinol with the Board. A motion was made by L. Schield to place Marinol on prior authorization. The motion was seconded by K. Kram. There was no public comment. This topic will be reviewed at the next meeting.

Skin pigment products review
B. Joyce reviewed skin pigment products with the Board. A motion was made by M. Quast to allow the department to manage the class of skin pigment products through prior authorization.

The motion was seconded by J. Hostetter. There was no public comment. This topic will be reviewed at the next meeting.

Inhaled corticosteroid/long-acting beta-2 adrenergic agonist combination products review
A. Murphy reviewed inhaled corticosteroid/LABA combination products with the Board. Recommendations include quantity limits allowing for 2 inhalers of albuterol per 2 months, MTM management for asthma, and prior authorization for appropriate utilization. J. Hostetter made a motion to place inhaled corticosteroids/LABA combination products on prior authorization. P. Woodrow seconded the motion. There was no public comment .This topic will be reviewed at the next meeting.

IBS medications review
B. Joyce reviewed IBS medications with the Board. There was no public comment. L. Schield made a motion to allow the department to manage the class through prior authorization. K. Kram seconded the motion. This topic will be reviewed at the next meeting.

Ulcerative colitis medications review
B. Joyce reviewed ulcerative colitis medications with the Board. There was no public comment. J. Hostetter made a motion to allow the department to manage the class through prior authorization. L. Schield seconded the motion. This topic will be reviewed at the next meeting.

SGLT2 inhibitors review
B. Joyce reviewed SGLT2 medications with the Board. B. Haas, representing AstraZeneca, spoke on behalf of Farxiga. J. Stoffel, representing Janssen, spoke on behalf of Invokana. T. Schmidt made a motion to allow the department to manage the class through prior authorization. J. Hostetter seconded the motion. This topic will be reviewed at the next meeting.

Immediate release oxycodone review
B. Joyce reviewed immediate release oxycodone utilization with the Board. The department would like guidance on the appropriate use of higher dosages of oxycodone immediate release without evidence of a long-acting agent. M. Quast made a motion to place high dose immediate release oxycodone on prior authorization. T. Schmidt seconded the motion. This topic will be reviewed at the next meeting.

Immediate release narcotics in conjunction with immediate release narcotic combinations review
B. Joyce reviewed narcotics in conjunction with immediate release narcotic combination products. The committee recommended drug-drug edits as well as prescriber education.

Inhaled anti-infectives for cystic fibrosis review
B. Joyce reviewed anti-infectives for cystic fibrosis with the Board. There was no public comment. J. Hostetter made a motion to allow the department to manage the class through prior authorization. T. Schmidt seconded the motion. This topic will be reviewed at the next meeting.

Leukotriene modifiers review
B. Joyce reviewed leukotriene modifiers with the Board. There was no public comment. J. Hostetter made a motion to allow the department to manage the class through prior authorization. K. Kram seconded the motion. This topic will be reviewed at the next meeting.

Gabapentin update
A. Murphy reviewed gabapentin data and quantity limit suggestions. The department will send a letter/survey to prescribers of gabapentin to let them know of any changes.

Criteria recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and are usually consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria and will be used in future DUR cycles. C. McCleary moved to approve the new criteria and K. Kram seconded the motion. Chair W. Brown called for a voice vote. The motion passed with no audible dissent.

The next DUR Board meeting will be held December 2 in Bismarck. L. Schield made a motion to adjourn the meeting. J. Hostetter seconded. The motion passed with no audible dissent. W. Brown adjourned the meeting.